COVİD-19 Enfeksiyonu ve Guillain Barré Sendromu: Olgu Sunumu

Öz

Coronavirüs pandemisi (COVID-19) Aralık 2019’da Çin’in Wuhan kentinden başlayarak tüm dünyayı etkisi altına alarak küresel değişikliklere yol açtı. Akut solunum sendromu koronavirüs 2(SARS-CoV-2) olarak tanımlanmaktadır. SARS-CoV-2’nin baş ağrısı, mide bulantısı, baş dönmesi, anosmi, aguzi ve periferik sinir sistemi semptomları gibi nörolojik bulgular ile ilişkili olduğu bildirilmiştir. Guillain-Barré sendromu (GBS), periferik sinir sisteminin enflamatuar hastalığıdır. Hastalığın nörolojik etkilerinin öneminin vurgulandığı nörolojik belirtiler rapor edilmiştir. GBS'nin çeşitli enfeksiyonlar sonrası ortaya çıkabilir. Olguda yaygın kas ağrısı, deride kaşıntı, döküntü ve hareket etmede zorluk şikayeti ile hastaneye başvurdu. Semptomlar arasında yürüyememe ve kolunu kaldırarak yemek yemede zorluk yer alıyordu. Bu doğrultuda COVID-19 enfeksiyonu ile ilişkili olabilecek olgu sunumun gözden geçirmesini amaçladık.

Anahtar Kelimeler

• Covid-19
• Guillan Barre sendromu
• Nörolojik bulgu

COVID-19 Infection and Guillain Barré Syndrome Case Report

Öz

The coronavirus pandemic (COVID-19) has caused global changes by affecting the whole world, starting from the Chinese city of Wuhan in December 2019. Acute respiratory syndrome is defined as coronavirus 2(SARS-CoV-2). SARS-CoV-2 has been reported to be associated with neurological signs such as headache, nausea, dizziness, anosmia, agusia, and peripheral nervous system symptoms. Guillain-Barré syndrome (GBS) is an inflammatory disease of the peripheral nervous system. Neurological symptom has reported, emphasizing the importance neurological effects of the disease. GBS can occur after various infections. The patient was admitted to the hospital with complaints of widespread muscle pain, skin itching, rash and difficulty in movement. Symptoms included the inability to walk and difficulty eating by lifting his arm. We aimed to review the case report that may be related to COVID-19 infection.

Anahtar Kelimeler

• Covid-19
• Guillain Barré Syndrome
• Neurological finding

Kaynakça

1. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268(9):3059-3071. doi:10.1007/s00415-021-10406-y
2. Mirian A, Nicolle MW, Budhram A. Guillain-Barré syndrome. CMAJ. 2021;193(11):378. doi:10.1503/cmaj.202710
3. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi:10.1001/jamaneurol.2020.1127
4. Gençler OS. Neurological Symptoms in Hospitalized Patients with COVID-19 Diagnosis and theRelationship with Disease Severity. YIU Saglik Bil Derg. 2021;2:76-82. doi.org/10.51261/yiu.2021.00037
5. 5. Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci. 2020;41(7):1667-1671. doi:10.1007/s10072-020-04486-3
6. Topçuoğlu MA, Öztürk Ş. Neurological Spectrum of COVID-19: A Practical Review. Turk J Neurol 2021;27(1):6-8. doi:10.4274/tnd.2021.92891
7. Ünlütürk Z, Öncel ÇH, Haytı B, Erdoğan Ç. Different Guillain-Barré Syndrome Variants Associated with COVID-19: Report of 4 Clinical Cases. Turk J Neurol. 2022; 28(1):51-54
8. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383-384. doi:10.1016/S1474-4422(20)30109-5

9. El Otmani H, El Moutawakil B, Rafai MA, Benna NE, Kettani CE, Soussi M. et al. Covid-19 and Guillain-Barré syndrome: More than a coincidence! Rev Neurol (Paris). 2020;176(6):518-519. doi:10.1016/j.neurol.2020.04.007
10. Palaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C. et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3517-3529. doi:10.1111/ene.14860